DK3238709T3 - Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme - Google Patents
Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme Download PDFInfo
- Publication number
- DK3238709T3 DK3238709T3 DK17175794.1T DK17175794T DK3238709T3 DK 3238709 T3 DK3238709 T3 DK 3238709T3 DK 17175794 T DK17175794 T DK 17175794T DK 3238709 T3 DK3238709 T3 DK 3238709T3
- Authority
- DK
- Denmark
- Prior art keywords
- lipofile
- pharmaceuticals
- preparation
- methods
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480259P | 2011-04-28 | 2011-04-28 | |
| EP12719541.0A EP2701684B1 (en) | 2011-04-28 | 2012-04-20 | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3238709T3 true DK3238709T3 (da) | 2020-09-28 |
Family
ID=46045121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17175794.1T DK3238709T3 (da) | 2011-04-28 | 2012-04-20 | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme |
| DK12719541.0T DK2701684T3 (da) | 2011-04-28 | 2012-04-20 | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af disse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12719541.0T DK2701684T3 (da) | 2011-04-28 | 2012-04-20 | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af disse |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9364433B2 (da) |
| EP (2) | EP3238709B1 (da) |
| JP (2) | JP6080312B2 (da) |
| CN (2) | CN103635179B (da) |
| AR (1) | AR086115A1 (da) |
| AU (1) | AU2012250050B2 (da) |
| CA (1) | CA2834262C (da) |
| DK (2) | DK3238709T3 (da) |
| ES (2) | ES2822350T3 (da) |
| HU (2) | HUE034480T2 (da) |
| IL (1) | IL229067B (da) |
| MX (2) | MX360638B (da) |
| PL (2) | PL2701684T3 (da) |
| TW (1) | TWI626059B (da) |
| WO (1) | WO2012148799A1 (da) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| WO2011039637A2 (en) | 2009-10-02 | 2011-04-07 | Foamix Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| NZ613167A (en) * | 2010-12-16 | 2015-09-25 | Univ Texas | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| ES2822350T3 (es) * | 2011-04-28 | 2021-04-30 | Platform Brightworks Two Ltd | Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas |
| US20140178479A1 (en) * | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| GR20120100242A (el) * | 2012-05-04 | 2014-01-02 | Micrel Ιατρικα Μηχανηματα Α.Ε., | Αντλια και προγεμισμενος ασκος/σετ αναλγησιας |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| WO2015037659A1 (ja) * | 2013-09-13 | 2015-03-19 | 株式会社医薬分子設計研究所 | 水溶液製剤及びその製造方法 |
| MX389323B (es) | 2013-12-03 | 2025-03-20 | Univ Northwestern | Particulas liposomales, metodos para elaborarlas y sus usos. |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| WO2015176161A1 (en) | 2014-05-23 | 2015-11-26 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| US11696883B2 (en) | 2014-05-23 | 2023-07-11 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| CN105394045B (zh) * | 2014-09-04 | 2020-02-14 | 中国科学院上海巴斯德研究所 | 一种肠道病毒的小分子化合物抑制剂及其应用 |
| US11266621B1 (en) | 2014-10-02 | 2022-03-08 | Exela Sterile Medicines Llc | Methocarbamol composition and related methods |
| WO2016059590A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of small molecule drugs and process for its preparation |
| TWI516520B (zh) | 2014-10-31 | 2016-01-11 | 財團法人工業技術研究院 | 波長轉換聚合物、其製法及包含其之波長轉換裝置 |
| PL3347009T3 (pl) | 2015-07-08 | 2022-02-07 | Triple Hair Inc. | Kompozycja zawierająca resweratrol i melatoninę ograniczająca wypadanie włosów i/lub zwiększająca odrastanie włosów |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US20170239250A1 (en) | 2016-02-19 | 2017-08-24 | Eagle Pharmaceuticals, Inc. | Pemetrexed formulations |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| CN105837556B (zh) * | 2016-04-11 | 2018-10-26 | 上海工程技术大学 | 一种来那度胺与烟酰胺共晶的制备方法 |
| WO2018022802A1 (en) * | 2016-07-26 | 2018-02-01 | University Of Southern California | Selective bromodomain inhibition of fungal bdf1 |
| IL265100B2 (en) * | 2016-08-31 | 2023-11-01 | Taro Pharma Ind | Fenoldopam topical formulations for treating skin disorders |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| CN106841100A (zh) * | 2016-12-28 | 2017-06-13 | 北京医药集团有限责任公司 | 一种基于近红外光谱技术的小规格口服固体制剂中活性药物成分快速测定方法 |
| EP3607074A4 (en) * | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| CA3059435A1 (en) * | 2017-04-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Therapeutic neuropathic pain lotion |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP3866783A4 (en) * | 2018-10-16 | 2022-08-03 | US Nano Food & Drug Inc | INTRATUMOR INJECTION FORMULATION |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2020092016A1 (en) * | 2018-10-31 | 2020-05-07 | Systamedic Inc. | Autophagy activators and inhibitors of ferroptosis for preventing acute renal failure and neurotoxcity induced by certain antibiotics |
| CN109627148B (zh) * | 2018-11-28 | 2021-09-03 | 中国农业科学院麻类研究所 | 一种大麻二酚的制备方法、制得的大麻二酚及其用途 |
| AU2020236525B2 (en) | 2019-03-08 | 2022-02-03 | Taro Pharmaceutical Industries Ltd. | Stable topical compositions of Fenoldopam |
| EP3938507A4 (en) | 2019-03-11 | 2023-02-22 | ModernaTX, Inc. | PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION |
| US20220387416A1 (en) * | 2019-10-25 | 2022-12-08 | Cmc Pharmaceuticals, Inc. | Atropine-scopolamine with enhanced stability |
| EP4069222A4 (en) | 2019-12-04 | 2023-12-27 | Resq Pharmaceuticals LLC | Methods and compositions for treating edema refractory to oral diuretics |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| CN114181211B (zh) * | 2020-09-14 | 2024-05-28 | 鲁南制药集团股份有限公司 | 一种酮咯酸与苯甲酰胺共晶体及其制备方法 |
| CN112697945A (zh) * | 2020-12-18 | 2021-04-23 | 卓和药业集团有限公司 | 泊沙康唑肠溶片含量的分析方法 |
| CN113274379B (zh) * | 2021-05-25 | 2023-04-25 | 湖北工业大学 | Bephenium Hydroxynaphthoate在制备抗EV71药物的应用 |
| CN113768937B (zh) * | 2021-11-15 | 2022-04-08 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
| US20230210857A1 (en) * | 2021-12-27 | 2023-07-06 | Enalare Therapeutics Inc. | Respiratory stimulant parenteral formulations |
| CN115721607B (zh) * | 2022-11-19 | 2023-07-21 | 华夏生生药业(北京)有限公司 | 一种乳酸左氧氟沙星注射液及其制备方法 |
| US20250032417A1 (en) | 2023-07-24 | 2025-01-30 | Hyloris Developments Sa | Lyophilized metolazone formulation for parenteral administration |
| WO2025054148A1 (en) * | 2023-09-07 | 2025-03-13 | Cfd Research Corporation | Co-administration of astemizole and an anticancer agent to treat cancer |
| CN118121554A (zh) * | 2024-03-14 | 2024-06-04 | 天津市保灵动物保健品有限公司 | 盐酸特比萘芬片剂 |
| CN119499175A (zh) * | 2024-11-23 | 2025-02-25 | 江西赣南海欣药业股份有限公司 | 一种注射用法莫替丁及其制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS475827Y1 (da) | 1970-04-02 | 1972-02-29 | ||
| JPS475827A (da) * | 1971-08-27 | 1972-03-29 | ||
| AU461715B2 (en) * | 1972-01-21 | 1975-05-19 | American Home Products Corporation | Parenteral benzodiazepine compositions |
| DE3316510A1 (de) | 1983-05-06 | 1984-11-08 | Bayer Ag | Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen |
| US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
| DE3702105A1 (de) | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| JPH01242525A (ja) | 1988-03-25 | 1989-09-27 | Nippon Nohyaku Co Ltd | 抗真菌外用剤 |
| US5430057A (en) | 1993-09-30 | 1995-07-04 | Board Of Regents, The University Of Texas System | Parenteral busulfan for treatment of malignant disease |
| US5869474A (en) * | 1997-05-16 | 1999-02-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Low dosage treatment for cocaine craving and withdrawal |
| US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US7179475B1 (en) | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| WO2000071163A1 (en) | 1999-05-24 | 2000-11-30 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| DE60020382T2 (de) * | 1999-09-21 | 2006-01-26 | Skyepharma Canada Inc., Verdun | Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB2365770B (en) | 2000-08-18 | 2002-07-31 | Diomed Dev Ltd | Antifungal ketoconazole composition for topical use |
| US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| US20030072807A1 (en) | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| JP2002322056A (ja) | 2001-04-27 | 2002-11-08 | Nippon Kayaku Co Ltd | トリアゾール誘導体の溶液製剤 |
| US6878693B2 (en) | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
| US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| US6991800B2 (en) | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| WO2004014431A1 (en) | 2002-08-12 | 2004-02-19 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
| ZA200409537B (en) | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
| US9259390B2 (en) * | 2003-08-13 | 2016-02-16 | The University Of Houston System | Parenteral and oral formulations of benzimidazoles |
| GB0412866D0 (en) | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
| FR2872703B1 (fr) | 2004-07-07 | 2006-10-06 | Ethypharm Sa | Nanoparticules polymeriques composites |
| US20060116404A1 (en) | 2004-09-24 | 2006-06-01 | Gary Robinson | CAI-based systems and methods for the localized treatment of ocular and other diseases |
| WO2006105399A1 (en) | 2005-03-31 | 2006-10-05 | Bristol-Myers Squibb Company | Methods for administering ixabepilone |
| CA2613389A1 (en) | 2005-06-27 | 2007-01-04 | Barrier Therapeutics, Inc. | Micogel topical formulations |
| ITMI20051826A1 (it) | 2005-09-29 | 2007-03-30 | Novachem S A | Kit per la somministrazione parenterale di medicamenti |
| US20070082870A1 (en) | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| CA2626016A1 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| EP2026771B1 (en) | 2006-01-23 | 2009-10-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Microspheres comprising nanocapsules containing a lipophilic drug |
| US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| AU2007355106A1 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
| KR20100075475A (ko) | 2007-09-05 | 2010-07-02 | 가부시키가이샤 폴라 파마 | 의약 조성물 |
| PL2200588T3 (pl) * | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
| US20090253712A1 (en) | 2008-04-03 | 2009-10-08 | Semmelweis Egyetem | Aqueous solvent system for solubilization of azole compounds |
| WO2009139925A1 (en) | 2008-05-16 | 2009-11-19 | Panacea Pharmaceuticals, Inc. | Methods for the treatment of brain edema |
| MX2011008204A (es) | 2009-02-05 | 2011-12-06 | Targeted Delivery Technologies Ltd | Metodos para reducir la proliferacion y viabilidad de los agentes microbianos. |
| CN102387785B (zh) | 2009-04-09 | 2017-08-25 | 宝丽制药股份有限公司 | 抗真菌药物组合物 |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| NZ613167A (en) * | 2010-12-16 | 2015-09-25 | Univ Texas | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| ES2822350T3 (es) * | 2011-04-28 | 2021-04-30 | Platform Brightworks Two Ltd | Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas |
-
2012
- 2012-04-20 ES ES17175794T patent/ES2822350T3/es active Active
- 2012-04-20 CN CN201280032690.8A patent/CN103635179B/zh active Active
- 2012-04-20 EP EP17175794.1A patent/EP3238709B1/en active Active
- 2012-04-20 EP EP12719541.0A patent/EP2701684B1/en active Active
- 2012-04-20 US US13/452,033 patent/US9364433B2/en active Active
- 2012-04-20 CA CA2834262A patent/CA2834262C/en active Active
- 2012-04-20 AU AU2012250050A patent/AU2012250050B2/en active Active
- 2012-04-20 HU HUE12719541A patent/HUE034480T2/en unknown
- 2012-04-20 WO PCT/US2012/034361 patent/WO2012148799A1/en not_active Ceased
- 2012-04-20 DK DK17175794.1T patent/DK3238709T3/da active
- 2012-04-20 JP JP2014508441A patent/JP6080312B2/ja active Active
- 2012-04-20 CN CN201711217375.3A patent/CN107970209B/zh active Active
- 2012-04-20 PL PL12719541T patent/PL2701684T3/pl unknown
- 2012-04-20 ES ES12719541.0T patent/ES2640572T3/es active Active
- 2012-04-20 DK DK12719541.0T patent/DK2701684T3/da active
- 2012-04-20 MX MX2013012579A patent/MX360638B/es active IP Right Grant
- 2012-04-20 PL PL17175794T patent/PL3238709T3/pl unknown
- 2012-04-20 HU HUE17175794A patent/HUE051400T2/hu unknown
- 2012-04-20 MX MX2018013788A patent/MX380805B/es unknown
- 2012-04-25 TW TW101114722A patent/TWI626059B/zh active
- 2012-04-26 AR ARP120101455A patent/AR086115A1/es not_active Application Discontinuation
-
2013
- 2013-10-24 IL IL229067A patent/IL229067B/en active IP Right Grant
-
2016
- 2016-05-13 US US15/154,919 patent/US9724345B2/en active Active
- 2016-10-24 JP JP2016208029A patent/JP2017014293A/ja active Pending
-
2017
- 2017-03-07 US US15/451,748 patent/US10028949B2/en active Active
-
2018
- 2018-06-21 US US16/014,908 patent/US10548890B2/en active Active
-
2020
- 2020-01-17 US US16/746,460 patent/US11045466B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
| IL272539B (en) | Compositions and methods for immunotherapy | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK2800565T3 (da) | Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK3290415T3 (da) | Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme | |
| DK2704703T3 (da) | Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf | |
| CO7020859A2 (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
| DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| DK2718270T3 (da) | Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet | |
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| DK3777840T3 (da) | Rna-formulering til immunterapi | |
| DK3141548T3 (da) | Fremgangsmåder og mellemprodukter til fremstilling af azaindoler | |
| CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| DK3378862T3 (da) | Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose | |
| DK4082530T5 (da) | Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK3252160T3 (da) | Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| DK3050972T3 (da) | Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider | |
| DK2489670T3 (da) | Fremgangsmåde til fremstilling af aminosyre-chelatforbindelser, aminosyre-chelatforbindelser og anvendelse af aminosyre-chelatforbindelser | |
| DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
| DK2616035T3 (da) | Indretning til at hjælpe med at gå med støtte | |
| DK2627656T3 (da) | Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf | |
| HUE045612T2 (hu) | Immunszuppresszáns készítmények |